AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development, and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in more than 100 countries, and its innovative medicines are used by millions of patients worldwide.
Between 2009 and 2011, AstraZeneca (US, Canada, MedImmune) (may be referred to as the “entities” from this point forward) consolidated onto a centralized, enterprise resource planning (ERP) hub to unify and standardize the entities under one chart of accounts, close cycles, and reporting capabilities. This consolidation—called the North America Transaction Processing project—facilitated alignment from an actual reporting perspective, but it left a large gap related to budgeting and forecasting, as each entity had separate systems, processes, and procedures for these functions.
The entities needed to consolidate, integrate, and standardize all planning, forecasting, and reporting functionalities into one central system from the previously disparate systems used by the entities to enable an enterprisewide view of planning data across all three North American entities. This had the additional benefit of allowing the new system to be supported by a center of excellence and utilizing fewer Hyperion administrator resources across the business. Additionally, the company needed to develop more efficient reporting capabilities to better meet company requirements for analytics.
AstraZeneca (US, Canada, MedImmune)implemented Oracle Hyperion Planning to provide a centralized reporting source for planning data and to adhere to the standard ERP chart of accounts while catering to the unique forecasting needs of each entity—such as gross margin, expenses, headcount, and working capital—in a multicurrency environment.
With the implementation, the entities gained a sophisticated solution that consists of separate applications for various planning and reporting functions by entity, and a unique profit and loss planning functionality. The architecture’s design provides flexibility for each entity to conduct calculations and forecasting processes that are specific to its business, while maintaining consistent master data across all applications for integrated enterprisewide planning.
The entities chose Oracle Hyperion Planning due to the solution’s ability to scale to support large, complex data volumes, as well as its reputation as an industry leader in enterprise planning and reporting solutions.
“We are extremely confident in Oracle’s ability to manage the large volume of data created by our unique business functions,” said Karen Smith – senior director, operations/G&A finance
“In addition, Oracle Consulting put a real focus on addressing our business needs. It worked really hard to match Oracle’s technical solution to our unique needs, rather than the other way around.”
AstraZeneca worked with Oracle Consulting to focus on matching the configuration of Oracle Hyperion Planning to the company’s specific business needs. The company went through approximately six weeks of prototyping, presenting results to the chief financial officers of each operating entity throughout the process. From there, the entities worked with program managers to capture solution requirements, then to design, configure, and build, while incorporating changes into each development iteration. The company went through three iterations before configuring the final solution.